| abstract |
A method of preventing or treating cutaneous pigmentation disease in a subject in need thereof, includes: providing a pharmaceutical composition comprising SDF1, an inducer or activator of SDF1, as an active ingredient; and administering the pharmaceutical composition to the subject, wherein the cutaneous pigmentation is prevented or treated, and the cutaneous pigmentation disease is selected from the group consisting of melasma, freckles, lentigo, nevus, pigmentation by drugs, pigmentation after inflammation and hyperpigmentation incurred from dermatitis. |